AAAAAA
Results:
1-8
|
Results: 8
Authors:
Mundasad, MV
Novack, GD
Allgood, VE
Evans, RM
Gorden, JC
Yerxa, BR
Citation: Mv. Mundasad et al., Ocular safety of INS365 ophthalmic solution: A P2Y(2) agonist in healthy subjects, J OCUL PH T, 17(2), 2001, pp. 173-179
Authors:
Novack, GD
Citation: Gd. Novack, Financing new drug development in ophthalmology, J GLAUCOMA, 9(2), 2000, pp. 195-199
Authors:
Novack, GD
Crockett, RS
Citation: Gd. Novack et Rs. Crockett, Submission of data sets to journals: What's the real issue?, ARCH OPHTH, 118(12), 2000, pp. 1706-1706
Authors:
Novack, GD
Citation: Gd. Novack, Update on regulatory review intervals for ophthalmic new drug applicationsat the United States food and drug administration, AM J OPHTH, 130(5), 2000, pp. 664-665
Authors:
Shulman, DG
Lothringer, LL
Rubin, JM
Briggs, RB
Howes, J
Novack, GD
Hart, K
Citation: Dg. Shulman et al., A randomized, double masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis, OPHTHALMOL, 106(2), 1999, pp. 362-369
Authors:
Novack, GD
Citation: Gd. Novack, ARVO commercial relationships policy: Financial disclosure in ARVO presentations and publications, INV OPHTH V, 40(12), 1999, pp. 2765-2766
Authors:
Shellenberger, MK
Groves, L
Shah, JM
Novack, GD
Citation: Mk. Shellenberger et al., A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state, DRUG META D, 27(2), 1999, pp. 201-204
Authors:
Caldwell, D
Cohen, GR
Davis, J
DeBarge, LR
Foley, J
Foster, CS
Fox, K
Friedlaender, M
John, G
Kaufman, A
Nozik, R
Olander, K
Ostrov, C
Raizman, M
Rosenbaum, J
Sall, K
Sheppard, J
Stewart, D
Stewart, W
Tauber, J
Trocme, S
Zimmerman, P
Howes, J
Coultas, S
Crockett, RS
Novack, GD
Strahlman, ER
Neumann, R
Citation: D. Caldwell et al., Controlled evaluation of loteprednol etabonate and prednisolone acetate inthe treatment of acute anterior uveitis, AM J OPHTH, 127(5), 1999, pp. 537-544
Risultati:
1-8
|